{"schema_version":"secwatch.filing_event.v1","accession":"0001641172-25-010495","form_type":"8-K","ticker":"USAQ","cik":"0000856984","company_name":"QHSLab, Inc.","filed_at":"2025-05-15T23:59:59+00:00","discovered_at":"2026-05-14T18:02:51.482712+00:00","generated_at":"2026-05-21T06:54:38.770626+00:00","sec_items":["7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"QHSLab Q1 revenue up 32% to $645K; gross margin expands to 66.6%","bullets":["Total revenue $645,419 vs $488,587 in Q1 2024, a 32.1% increase.","Gross margin improved to 66.6% from 58.6% on favorable product mix.","ISP revenue rose 28% to $162,502; Allergy Diagnostics up 11.7% to $264,913.","New clinical study performance obligations contributed $89,100 in revenue."],"urls":{"canonical":"https://secwatch.observer/filing/0001641172-25-010495","json":"https://secwatch.observer/filing/0001641172-25-010495.json","markdown":"https://secwatch.observer/filing/0001641172-25-010495.md","text":"https://secwatch.observer/filing/0001641172-25-010495.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/856984/000164117225010495/0001641172-25-010495-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/856984/000164117225010495/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T06:54:38.770626+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}